🔍

GLAND - Gland Pharma

📊 NSE: GLAND 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/13/2025 22:22

📢 Recent Corporate Announcements

Gland Pharma to Host Q4 FY26 Earnings Conference Call on May 15, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 21 Apr 2026, 05:16 PM

Gland Pharma Limited has scheduled its earnings conference call for Friday, May 15, 2026, at 18:30 IST. The call will focus on the company's financial performance and business updates for the fourth quarter and the full financial year ended March 31, 2026. The session is planned for a duration of 60 minutes and will include a management discussion followed by a Q&A session. Audio recordings and transcripts will be uploaded to the company's website following the event.

Earnings call scheduled for May 15, 2026, at 18:30 hours IST.
Discussion to cover financial results for Q4 FY26 and the full financial year 2025-26.
Management session expected to last 60 minutes including Q&A.
Universal dial-in numbers provided: +91 22 6280 1516 and +91 22 7115 8875.
International toll-free access available for USA, UK, Singapore, and Hong Kong.

💡 Investors should monitor the call on May 15 for management commentary on growth guidance and margin performance. No immediate action is required as this is a routine scheduling announcement.

Gland Pharma Seeks Shareholder Approval for Reappointment of Naina Lal Kidwai as Director

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 13 Apr 2026, 04:43 PM

Gland Pharma has issued a postal ballot notice to seek shareholder approval for the reappointment of Ms. Naina Lal Kidwai as an Independent Director. The special resolution also includes a proposal to consider commission on profits as part of her remuneration package. The e-voting process is scheduled to take place between April 14, 2026, and May 13, 2026. Shareholders on record as of the cut-off date of April 10, 2026, are eligible to participate in the voting process.

Special resolution proposed for the reappointment of Ms. Naina Lal Kidwai as an Independent Director.
Proposal includes the payment of commission on profits as remuneration to the director.
Remote e-voting period runs from April 14, 2026 (9:00 AM) to May 13, 2026 (5:00 PM).
Cut-off date for determining voting eligibility is set for April 10, 2026.
Final results of the postal ballot will be announced on or before May 15, 2026.

💡 This is a routine governance matter; investors should review the proposed remuneration terms but no immediate portfolio action is required. The reappointment of an experienced director like Naina Lal Kidwai is generally seen as a positive for board quality.

Gland Pharma Submits Quarterly SEBI Compliance Certificate for Q4 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 13 Apr 2026, 04:09 PM

Gland Pharma Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The report, provided by the Registrar and Share Transfer Agent, MUFG Intime India Private Limited, covers the quarter ending March 31, 2026. The Registrar confirmed that there were no requests for the dematerialization or rematerialization of equity shares during this timeframe. This is a standard regulatory disclosure required for all listed entities in India to ensure share records are accurately maintained.

Compliance certificate filed for the quarter ended March 31, 2026.
Registrar MUFG Intime India Private Limited confirmed zero demat or remat requests were received.
The filing adheres to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.

💡 This is a routine administrative filing with no impact on company fundamentals. Investors should continue to monitor the company's operational performance and upcoming financial results.

Gland Pharma Re-appoints Naina Lal Kidwai as Independent Director for 5-Year Term

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 09 Apr 2026, 07:07 PM

Gland Pharma's Board has approved the re-appointment of Ms. Naina Lal Kidwai as an Independent Director for a second five-year term. This term will commence on May 17, 2026, and extend until May 16, 2031, subject to shareholder approval via postal ballot. Ms. Kidwai is a highly distinguished professional, currently serving as Chairman of Rothschild & Co India and holding a Padma Shri award. Her continued presence on the board is expected to provide strong corporate governance and strategic oversight for the company.

Re-appointment of Ms. Naina Lal Kidwai for a second term of 5 consecutive years.
New term effective from May 17, 2026, through May 16, 2031.
Shareholder approval to be sought via postal ballot and e-voting as per SEBI regulations.
Ms. Kidwai brings extensive experience as former Chairman of HSBC India and current Chairman of Rothschild & Co India.

💡 No immediate action is required as this is a routine governance matter. The retention of a high-profile independent director like Ms. Kidwai is a positive signal for long-term corporate governance and board stability.

Gland Pharma to Close Trading Window from March 28 for Q4 and FY26 Audited Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Mar 2026, 12:30 PM

Gland Pharma Limited has informed the stock exchanges that its trading window for dealing in company securities will be closed starting Saturday, March 28, 2026. This closure is a mandatory compliance step under SEBI (Prohibition of Insider Trading) Regulations ahead of the audited financial results for the quarter and year ending March 31, 2026. The window will remain closed until 48 hours after the results are officially declared. The company will notify the specific date of the board meeting to approve these results in a separate future filing.

Trading window closure effective from March 28, 2026, for all designated persons.
Closure pertains to the audited financial results for the quarter and financial year ending March 31, 2026.
Trading restriction will be lifted 48 hours after the public announcement of the financial results.
Board meeting date for result approval to be intimated in due course.

💡 This is a routine regulatory announcement and does not require any immediate action from retail investors. Investors should look out for the upcoming board meeting date to track the company's year-end financial performance.

Gland Pharma Schedules One-on-One Meeting with Ventura Securities for March 23

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 18 Mar 2026, 05:04 PM

Gland Pharma Limited has informed the stock exchanges about a scheduled one-on-one meeting with Ventura Securities. The meeting is set to take place on March 23, 2026, as part of the company's regular engagement with institutional investors and analysts. This disclosure is a routine compliance requirement under Regulation 30 of SEBI (LODR) Regulations, 2015. Such meetings are standard practice for listed companies to discuss business outlooks within the framework of public information.

One-on-one meeting scheduled with Ventura Securities
Meeting date fixed for March 23, 2026
Compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Official intimation filed with BSE and NSE on March 18, 2026

💡 This is a routine administrative update; investors should monitor the company's website for any investor presentations or transcripts that may be released following the meeting.

Gland Pharma Schedules Non-Deal Roadshow with Elara (USA) for March 18-20, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Mar 2026, 03:43 PM

Gland Pharma Limited has announced a Non-Deal Roadshow (NDR) scheduled to take place from March 18 to March 20, 2026. The company will engage in one-on-one meetings with institutional investors and analysts, facilitated by Elara (USA). This initiative is part of the company's regular investor relations outreach to discuss business performance and strategy with the international investment community.

Three-day Non-Deal Roadshow (NDR) scheduled from March 18 to March 20, 2026.
Meetings will be conducted in a one-on-one format with institutional investors and analysts.
The roadshow is organized in collaboration with Elara (USA) targeting international stakeholders.
The schedule is subject to change based on the exigencies of the company or investors.

💡 No immediate action is required as this is a routine investor engagement; however, investors should watch for any subsequent analyst reports that may provide updated perspectives on the company.

Gland Pharma Schedules One-on-One Meeting with Sundaram Asset Management

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 11 Mar 2026, 05:32 PM

Gland Pharma Limited has announced a scheduled interaction with Sundaram Asset Management set for March 16, 2026. The meeting is categorized as a one-on-one session to discuss the company's business and performance. This disclosure is a routine regulatory requirement under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Investors should note that such meetings are standard practice for institutional engagement and typically do not involve the disclosure of unpublished price-sensitive information.

One-on-one meeting scheduled with Sundaram Asset Management on March 16, 2026
Official intimation filed with BSE and NSE on March 11, 2026
Meeting is subject to change based on exigencies from either party
Compliance maintained under Regulation 30 of SEBI LODR Regulations

💡 No immediate action is required as this is a routine investor relations activity. Investors may monitor the company's website for any subsequent investor presentations or transcripts related to this meeting.

Gland Pharma Schedules Institutional Investor Meetings and Plant Visit in March 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Mar 2026, 05:22 PM

Gland Pharma has announced a series of interactions with institutional investors and analysts scheduled between March 12 and March 17, 2026. The schedule includes a plant visit arranged by Investec and one-on-one meetings with major funds like SBI Mutual Fund and Capital World Investors. These interactions are part of the company's regular engagement with the financial community to discuss business operations. While these meetings are routine, they often signal management's openness to discussing long-term strategy with key stakeholders.

Plant visit for investors arranged by Investec scheduled for March 12, 2026
One-on-one meeting with SBI Mutual Fund confirmed for March 13, 2026
Group meeting organized by Investec also set for March 13, 2026
One-on-one interaction with Capital World Investors scheduled for March 17, 2026

💡 No immediate action is required as this is a routine regulatory disclosure. Investors should watch for any subsequent investor presentations or transcripts that may provide updated guidance on the company's manufacturing outlook.

Gland Pharma to Attend Group Investor Meeting Arranged by Goldman Sachs on March 5

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 25 Feb 2026, 03:09 PM

Gland Pharma Limited has announced a group meeting with analysts and institutional investors scheduled for March 05, 2026. The meeting is being organized by Goldman Sachs and is part of the company's regular investor relations activities. This disclosure is made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Such meetings typically provide a platform for management to discuss business outlook and performance with the investment community.

Group meeting with analysts and institutional investors scheduled for March 05, 2026
Meeting is being organized by Goldman Sachs
Disclosure submitted under SEBI (LODR) Regulations, 2015
The schedule is subject to change due to exigencies on the part of the company or investors

💡 No immediate action is required as this is a routine disclosure; however, investors should monitor for any post-meeting transcripts or presentations for updates on business strategy.

Gland Pharma to Meet Renaissance Investment Managers on February 25, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 20 Feb 2026, 03:05 PM

Gland Pharma Limited has announced a one-on-one meeting with Renaissance Investment Managers scheduled for February 25, 2026. This interaction is part of the company's routine engagement with institutional investors to discuss business updates. The disclosure is made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Investors should note that the schedule is subject to change based on the availability of either party.

One-on-one meeting scheduled with Renaissance Investment Managers.
The meeting is set to take place on February 25, 2026.
Disclosure filed under SEBI (LODR) Regulations, 2015.
The schedule remains subject to change due to exigencies.

💡 No immediate action is required as this is a routine investor meeting. Investors may look for any subsequent investor presentations or transcripts that might be released following the interaction.

Gland Pharma to Meet Mirae Asset Investment Managers on February 23, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 18 Feb 2026, 12:22 PM

Gland Pharma Limited has scheduled a one-on-one meeting with Mirae Asset Investment Managers on February 23, 2026. This interaction is part of the company's routine engagement with institutional investors to discuss business updates. The meeting schedule was disclosed to the exchanges on February 18, 2026, in compliance with SEBI (LODR) Regulations. Such meetings typically involve discussions on the company's general business outlook and industry trends.

One-on-one meeting scheduled with Mirae Asset Investment Managers.
The meeting is set to take place on February 23, 2026.
Disclosure made in compliance with SEBI (LODR) Regulations, 2015.
The schedule is subject to change due to exigencies on either side.

💡 This is a routine corporate event; no specific action is needed. Investors should monitor the company's website for any investor presentations shared during this period.

Gland Pharma Appoints Dr. Jitendra Gangwal as VP of R&D to Lead Complex Product Development

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 18 Feb 2026, 12:06 PM

Gland Pharma has appointed Dr. Jitendra Gangwal as Vice-President of Research and Development, effective February 18, 2026. Dr. Gangwal brings over 24 years of experience in pharmaceutical R&D, having previously held leadership roles at Dr. Reddy’s, Glenmark, and Alkem Laboratories. His track record includes the development of 55+ products and filing 10+ patents, specifically in complex delivery systems like liposomes and peptides. This strategic hire is intended to bolster Gland Pharma's pipeline of high-value complex injectables for regulated global markets.

Dr. Jitendra Gangwal appointed as VP (R&D) with over 24 years of pharmaceutical experience.
Developed 55+ products across injections, ophthalmics, inhalation, and nasal routes.
Filed 10+ patents and led multiple 505(b)(2) and ANDA filings in previous roles.
Expertise in complex parenterals, nano-crystals, liposomes, and advanced polymer-based delivery systems.

💡 Investors should view this as a positive move to strengthen the company's core R&D capabilities. Monitor the pace of new ANDA filings and complex product approvals over the next 12-18 months to gauge the impact of this leadership change.

Gland Pharma Schedules One-on-One Investor Meeting with Investec on February 12

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Feb 2026, 05:06 PM

Gland Pharma Limited has announced a scheduled interaction with institutional investors. The company will hold a one-on-one meeting with Investec on February 12, 2026. This disclosure is a routine compliance filing under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Such meetings are standard practice for management to engage with the investment community regarding business outlook and performance.

One-on-one meeting scheduled with Investec.
The meeting is set to take place on February 12, 2026.
Filing made in compliance with SEBI LODR Regulation 30.
Schedule is subject to change based on exigencies of either party.

💡 No immediate action is required as this is a routine investor meeting; however, investors should watch for any post-meeting presentations or transcripts released to the exchanges.

Gland Pharma Gets USFDA Approval for Zoledronic Acid Injection; US Market Size $6.7 Million

🟢 POSITIVE ⭐ 6/10

REGULATORY 📅 06 Feb 2026, 11:11 AM

Gland Pharma has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Zoledronic Acid Injection (4 mg/100 mL) in single-dose bags. The product is indicated for treating Hypercalcemia of Malignancy, Multiple Myeloma, and Bone Metastases of Solid Tumors. According to IQVIA data, the product's US market sales were approximately USD 6.7 million for the twelve months ending November 2025. This approval strengthens Gland's sterile injectable portfolio in the key US market.

Received USFDA approval for Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/mL) Single-Dose Bags
Product is bioequivalent and therapeutically equivalent to the reference listed drug by InfoRLife
Target indications include Hypercalcemia of Malignancy and Multiple Myeloma
US market sales for the product were approximately USD 6.7 million for the year ending November 2025

💡 Investors should view this as a positive incremental addition to Gland's US portfolio, though the individual market size is modest. Monitor the company's ability to maintain its track record of USFDA approvals and market share gains in the generic injectables space.

View All GLAND Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 6% YoY to INR 14,869 million in Q2 FY26. The US segment grew 8% YoY to INR 8,005 million. Other regulated markets (Europe, Canada, Australia, NZ) grew 18% YoY in H1 FY26. Cenexi revenue grew 10% YoY in Euro terms to EUR 88 million for H1 FY26. ROW own product sales grew 19% YoY, though offset by a 53% decline in tech transfer/CMO revenue.

Geographic Revenue Split

US market accounts for approximately 54% of Q2 revenue (INR 8,005 million). ROW market contributed INR 1,635 million (approx. 11%). India market generated INR 665 million (approx. 4.5%). Other regulated markets and Cenexi operations in Europe constitute the remaining balance.

Profitability Margins

Consolidated EBITDA margin stood at 21% for Q2 FY26. The base business (excluding Cenexi) maintained a high adjusted EBITDA margin of 36% in H1 FY26. Cenexi's EBITDA losses narrowed from EUR 11 million to EUR 5 million YoY in H1 FY26, showing a positive trend toward the Q3 breakeven target.

EBITDA Margin

Consolidated EBITDA was INR 3,139 million (21% margin), up 6% YoY. Adjusted EBITDA for H1 FY26 was INR 7,092 million (24% margin). The margin is currently suppressed by Cenexi's operational losses but supported by the core business's 36% margin profile.

Capital Expenditure

Capex is strictly allocated to high ROCE initiatives including CDMO expansion, GLP-1 capacity, and complex injectable capabilities. Specific INR values for total planned capex were not disclosed in the available documents.

⚙️ Operational Drivers

Capacity Expansion

Expanding complex injectable manufacturing and adding GLP-1 capacity. A dedicated line for a large product is starting next quarter. Cenexi is targeting a EUR 50 million revenue run rate to achieve EBITDA breakeven.

Manufacturing Efficiency

Focusing on yield improvement and waste reduction through digitization. Cenexi is undergoing headcount optimization and finance/IT back-office integration with India to capture synergies.

📈 Strategic Growth

Expected Growth Rate

19%

Growth Strategy

Growth is driven by a shift toward a differentiated complex portfolio, including CDMO launches of auto-injectors and pen-device systems. The company is expanding into GLP-1 capacity and complex injectables. Turnaround of Cenexi via price increases and product mix optimization is expected to contribute to margin expansion. New product launches like Dalba (this quarter) and Cangrelor (future) are key drivers.

Products & Services

Injectables, CDMO services, auto-injectors, pen-device systems, and specialty segment medicines including Dalba and Cangrelor.

Brand Portfolio

Gland Pharma, Cenexi.

New Products/Services

New launches contributed 7% to US growth in Q2 FY26. Key upcoming products include Dalba and complex injectables using new manufacturing technologies.

Market Expansion

Expanding presence in regulated markets (US/Europe) through CDMO contracts and increasing penetration in ROW markets where own product sales grew 19%.

Strategic Alliances

CDMO partnerships with major firms like Eli Lilly and Dr. Reddy's (DRL) for tech transfer and manufacturing.

🌍 External Factors

Industry Trends

The industry is shifting toward complex injectables and CDMO outsourcing. Gland is positioning itself as a global innovation-led injectable company, moving away from simple generics to high-margin niche formulations to counter competitive pricing.

Competitive Landscape

Operates in a competitive pricing environment in the US. Competitors include other global injectable players and CDMOs.

Competitive Moat

Moat is built on complex manufacturing capabilities (auto-injectors, pen-devices) and a high-margin CDMO model. This is sustainable because these technologies are harder to replicate than standard injectable lines, creating higher switching costs for partners.

Macro Economic Sensitivity

Sensitive to the US regulatory and licensing environment; a 'wait and see' approach by US partners has slowed licensing, reducing milestone revenue by approximately 44% from normal levels.

Consumer Behavior

Increased demand for advanced delivery systems like auto-injectors and pen-devices in the specialty segment.

⚖️ Regulatory & Governance

Industry Regulations

Fontenay site GMP certification renewed through end of 2026 following an ANSM inspection in July. Compliance with high quality standards is maintained to ensure margin resilience in regulated markets.

⚠️ Risk Analysis

Key Uncertainties

Milestone revenue timing and US licensing slowdowns pose a 40-50% risk to the normal milestone revenue run rate. Cenexi's ability to hit the EUR 50 million Q3 target is critical for consolidated breakeven.